NEW YORK (AP) -- Forest Laboratories Inc. and Almirall SA said Wednesday that they will delay their filing for approval of a combination lung disease drug.
Forest and Almirall are developing a combination of Forest's drug Tudorza and the asthma drug formoterol as a treatment for chronic obstructive pulmonary disease. The companies had planned to file for approval during the fourth quarter.
Forest and Almirall, which is based in Spain, said they decided to delay the filing after discussions with the Food and Drug Administration. The companies will take more time to resolve concerns related to chemistry, manufacturing and controls.
Shares of Forest Laboratories fell 6 cents to close Wednesday trading at $43.28, and gave up 27 cents to $43.01 in aftermarket trading.